These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

436 related items for PubMed ID: 15571972

  • 1. Clinical potential of minocycline for neurodegenerative disorders.
    Blum D, Chtarto A, Tenenbaum L, Brotchi J, Levivier M.
    Neurobiol Dis; 2004 Dec; 17(3):359-66. PubMed ID: 15571972
    [Abstract] [Full Text] [Related]

  • 2. Clinical potential of minocycline for schizophrenia.
    Miyaoka T.
    CNS Neurol Disord Drug Targets; 2008 Oct; 7(4):376-81. PubMed ID: 18991666
    [Abstract] [Full Text] [Related]

  • 3. Coenzyme Q treatment of neurodegenerative diseases of aging.
    Galpern WR, Cudkowicz ME.
    Mitochondrion; 2007 Jun; 7 Suppl():S146-53. PubMed ID: 17485247
    [Abstract] [Full Text] [Related]

  • 4. [Is good old minocycline a new neuroprotective drug?].
    Melero-Fernández de Mera RM, García-Martínez E, Fernández-Gómez FJ, Hernández-Guijo JM, Aguirre N, Galindo MF, Jordán J.
    Rev Neurol; 2007 Jun; 47(1):31-8. PubMed ID: 18592478
    [Abstract] [Full Text] [Related]

  • 5. Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases.
    Gibrat C, Cicchetti F.
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar 30; 35(2):380-9. PubMed ID: 21111020
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Minocycline is not beneficial in a phenotypic mouse model of Huntington's disease.
    Diguet E, Rouland R, Tison F.
    Ann Neurol; 2003 Dec 30; 54(6):841-2. PubMed ID: 14681898
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis.
    Dunkel P, Chai CL, Sperlágh B, Huleatt PB, Mátyus P.
    Expert Opin Investig Drugs; 2012 Sep 30; 21(9):1267-308. PubMed ID: 22741814
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Tissue transglutaminase: a novel pharmacological target in preventing toxic protein aggregation in neurodegenerative diseases.
    Wilhelmus MM, van Dam AM, Drukarch B.
    Eur J Pharmacol; 2008 May 13; 585(2-3):464-72. PubMed ID: 18417122
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Minocycline fails to protect cerebellar granular cell cultures against malonate-induced cell death.
    Fernandez-Gomez FJ, Gomez-Lazaro M, Pastor D, Calvo S, Aguirre N, Galindo MF, Jordán J.
    Neurobiol Dis; 2005 Nov 13; 20(2):384-91. PubMed ID: 16242643
    [Abstract] [Full Text] [Related]

  • 18. Impacts of methylxanthines and adenosine receptors on neurodegeneration: human and experimental studies.
    Chen JF, Chern Y.
    Handb Exp Pharmacol; 2011 Nov 13; (200):267-310. PubMed ID: 20859800
    [Abstract] [Full Text] [Related]

  • 19. Minocycline in amyotrophic lateral sclerosis: a pilot study.
    Pontieri FE, Ricci A, Pellicano C, Benincasa D, Buttarelli FR.
    Neurol Sci; 2005 Oct 13; 26(4):285-7. PubMed ID: 16193258
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.